Outcomes and endpoints
PD, RA
SECONDARY
The outcomes assessed in the study were safety, tolerability, PK, PD, and efficacy of WBP216. The primary endpoint was the incidence of AEs associated with escalating doses of WBP216 while the secondary endpoints were the assessment of PK, PD, and the immunogenicity of WBP216. The exploratory endpoint was effectiveness of WBP216 in treating RA.